UPCC 19424: A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in P
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 855830
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
